A083790 Stock Overview
A biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
CG Invites Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,765.00 |
| 52 Week High | ₩4,505.00 |
| 52 Week Low | ₩2,250.00 |
| Beta | -0.078 |
| 11 Month Change | 6.76% |
| 3 Month Change | -26.27% |
| 1 Year Change | -37.09% |
| 33 Year Change | -64.14% |
| 5 Year Change | -71.98% |
| Change since IPO | -64.82% |
Recent News & Updates
Shareholder Returns
| A083790 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 6.3% | 0.2% | -0.6% |
| 1Y | -37.1% | 19.2% | 6.8% |
Return vs Industry: A083790 underperformed the KR Biotechs industry which returned 19.2% over the past year.
Return vs Market: A083790 underperformed the KR Market which returned 6.8% over the past year.
Price Volatility
| A083790 volatility | |
|---|---|
| A083790 Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in KR Market | 11.1% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A083790's share price has been volatile over the past 3 months.
Volatility Over Time: A083790's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 68 | Joong-Myung Cho | www.cgxinc.com |
CG Invites Co., Ltd., a biopharma company, engages in the discovery and development of structural chemoproteiomics-based drugs in Korea. It offers Acelex (polmacoxib), an anti-inflammatory and pain relief drug, as well as CG-650, an anti-inflammatory drug, currently under phase 1 stage for the treatment of osteoarthritis; CG-651, an anti-inflammatory drug, currently under phase 1 stage for the treatment of neuropathic pain; and CG-652, an anti-inflammatory drug, currently under phase 1 stage for the treatment of rheumatoid arthritis. The company is also involved in the development of Ivaltinostat, an anti-cancer drug, currently under phase 2 stage for the treatment of pancreatic cancer and myelodysplastic syndrome, as well as preclinical stage for the treatment of acute myeloid leukemia and hepatocellular carcinoma; Camrelizumab, an anti-cancer drug, currently under phase 3 stage for the treatment of NSCLC; and Luxeptinib, an anti-cancer drug, currently under phase 1 stage for the treatment of acute myeloid leukemia, chronic lymphocytic leukemia, and non-hodgkin’s lymphoma.
CG Invites Co., Ltd. Fundamentals Summary
| A083790 fundamental statistics | |
|---|---|
| Market cap | ₩211.68b |
| Earnings (TTM) | -₩50.10b |
| Revenue (TTM) | ₩3.74b |
56.6x
P/S Ratio-4.2x
P/E RatioIs A083790 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A083790 income statement (TTM) | |
|---|---|
| Revenue | ₩3.74b |
| Cost of Revenue | ₩2.90b |
| Gross Profit | ₩836.26m |
| Other Expenses | ₩50.93b |
| Earnings | -₩50.10b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -654.35 |
| Gross Margin | 22.37% |
| Net Profit Margin | -1,339.86% |
| Debt/Equity Ratio | 28.6% |
How did A083790 perform over the long term?
See historical performance and comparison